Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.50 |
| ▸ | APOB | P04114 | 9/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137387 | 0.90 | MEN1 (0.57) | TACR1MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5359589 | 0.86 | MEN1 (0.51) | TACR1MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5137981 | 0.84 | OXTR (0.43) | MTTPAPOBHCRTR1HCRTR2 | |
| SCHEMBL5138006 | 0.84 | ALDH1A1 (0.50) | TACR1MEN1ALDH1A1KMT2AHCRTR1 | |
| SCHEMBL5136654 | 0.83 | MEN1 (0.49) | TACR1MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5373300 | 0.83 | MEN1 (0.46) | MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5135771 | 0.82 | MEN1 (0.51) | TACR1MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5136107 | 0.82 | MEN1 (0.51) | TACR1MEN1ALDH1A1KMT2ALTB4R2 | |
| SCHEMBL5995268 | 0.81 | OPRM1 (0.48) | TACR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5359612 | 0.81 | TACR1 (0.57) | MTTPTACR1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |